GRK5-IN-3 is a covalent inhibitor ofGRK5(G Protein-Coupled Receptor Kinase5). GRK5-IN-3 shows potent inhibitory effect toGRK5andGRK6withIC₅₀s of 0.22 μM and 0.41 μM, respectively^[1].

IC50: 0.22 μM (GRK5), 0.41 μM (GRK6)^[1]

GRK5 can be used to cancer, neurodegeneration, type 2 diabetes, heart failure and cardiovascular (CVD) research^[1].
GRK5-IN-3 (Compound 5) (0-333 μM; 0-4 h) inhibits GRK5 in a time-dependent manner with IC₅₀s of 59 μM (0 h), 11.3 μM (0.5 h), 6.2 μM (1 h), and 0.22 μM (4 h), respectively^[1].
GRK5-IN-3 (0-333 μM; 0-4 h) also shows selectivity to human GRK5 over bovine GRK2 and bovine GRK1, with IC₅₀s >100 μM (GRK1/2), respectively^[1].
GRK5-IN-3 (0-333 μM; 0-4 h) exerts inhibition against GRK5, while light activated ROS as substrate, with IC₅₀s of >100 μM (0 h), 4.2 μM (0.5 h), 3.4 μM (1 h), and 0.9 μM (4 h), respectively^[1].
GRK5-IN-3 (0-333 μM; 4 h) shows no inhibitory effect on mutant GRK5 (GRK5-C474S, Cys474 mutated to serine), with IC₅₀values >100 μM^[1].

443.46

C₂₃H₂₁N₇O₃

2410793-22-3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.